Clinical Research Program Trials and Eligibility
Throughout the last century the medical community has
witnessed dramatic changes in the methods of diagnosis
and treatment of cancer. Cancer research is no longer
conducted exclusively at large university cancer centers
or major metropolitan hospitals. Virginia Oncology Associates'
physicians have embraced clinical research as a critical
component of community-based oncology care. Through a
partnership with Duke University Oncology Consortium,
National Cancer Institute and US Oncology, VOA physicians
are able to provide cancer patients with innovative treatment
options and therapies. Virginia Oncology Associates offers
the largest clinical research program in all of Hampton
Roads. You do not have to leave the area to receive premier
cancer care. If you are interested in learning
more about our research program, please call the
VOA Research Department
(757) 466-8683 (South side) or (757)
873-9833 (peninsula).
BREAST
GYN
GASTROINTESTINAL
GENITOURINARY
LEUKEMIA & LYMPHOMA
LUNG CANCER
MULTIPLE MYELOMA
SOLID TUMORS
SARCOMA
SUPPORTIVE CARE
TRANSPLANT/HIGH-DOSE
SKIN
USO 07 132: A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NSABP PROTOCOL B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
USO # 07-119 (BETH Trial): A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab
CALGB 40101: Adriamycin/Cytoxan versus Taxol as
Adjuvant Therapy for Breast Cancer in Women with
0-3 Positive Axillary Lymph Nodes
USO 05-074: Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women with ErbB2- (HER2/neu-) Overexpressing Invasive Breast Cancer
USO 06-038: Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) plus Trastuzumab in HER2-Positive Earlt Stage Breast Cancer Patients
TailoRx;PACCT-1: Trial Assigning IndividuaLized Options for Treatment; Program for the Assessment of Clinical Cancer Tests
CTSU N063D/ALTTO BIG 2-06: A Randomized, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer / Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study
USO 06-185: Randomized Phase II Trial of Letrozole with or without Dasatinib as First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Post-Menopausal Breast Cancer that is Unresectable, Locally Recurrent or Metastatic
USO 06-166: Phase II, multicenter, open-label, clinical trial of Trabectedin(Yondelis) in Metastatic Breast Cancer Patients with triple negative profile (ER-,PR-,HER2-), HER2 overexpressing tumors and BRCA1 or BRCA2 mutation carriers.
NOTICE: As of June the group A (triple negative profile (ER-,PR-,HER-2-) has been closed for recruitment.
Duke Metastatic to Brain(DRCO_BR_2006_03): Phase II safety and Tolerability Study of Avastin When Added to Single Agent Chemotherapy to Treat Patients with Breast Cancer Metastatic to the Brain
Duke Triple Negative (DCRO_BR-2006_01): A Phase II Study of Abraxene, Carboplatin and Bevacizumab in "Triple Negative" (Demonstrating No Expression for Estrogen, Progesterone or HER2 Receptors) Metastatic Breast Cancer
USO 05076: A Randomized, Parallel Group, Open-Label, Active
Controlled, Multicenter Phase III Trial of Patupilone (EPO906)
versus Pegylated Liposomal Doxorubicin (Doxil/Caelyx) in
Taxane/Platinum Refractory/Resistant Patients with Recurrent
Epithelial Ovarian, Primary Fallopian or Primary Peritoneal
Cancer
GOG 0212: A Randomized Phase III Trial of Maintenance Chemotherapy
Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax
versus No Treatment until Documented Relapse in Women with Advanced
Ovarian or Primary Peritoneal Cancer who Achieve a Complete Clinical
Response to primary Platinum/Taxane Chemotherapy
GOG 218: A Phase III Trial of Carboplatin and Paclitaxel
plus placebo versus Carboplatin and Paclitaxel plus
concurrent Bevacizumab (NSC#704865, IND #7921) followed
by placebo, versus carboplatin and Paclitaxel plus concurrent
and extended Bevacizumab, in women with newly diagnosed,
previously untreated, stage III (sub optimal) and all
stage IV, epithelial ovarian or primary peritoneal cancer
USO 07-056: A Phase III, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma
USO 05-076: A Randomized, Parallel Group, Open-Label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) versus Pegylated Liposomal Doxorubicin (Doxil/Caelyx) in Taxane/Platinum Refractory/Resistant Patients with Recurrent Epitheleal Ovarian, Primary Fallopian or Primary Peritoneal Cancer (CEPO906A2303)
NSABP R-04: A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with
or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI)
of 5-Fluorouracil (5-FU) with or without Oxaliplatin in the Treatment of Patients with Operable
Carcinoma of the Rectum
USO 05-102: A randomized Phase II trial of pre-operative chemoradiotherapy with or without cetuximab (ERBITUX (R)) in locally-advanced adenocarcinoma of the rectum
Duke 8797: A Phase II Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas
CALGB 80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
US0 06-040: PHASE II TRIAL OF GEMCITABINE, CISPLATIN, AND SUNITINIB IN PATIENTS WITH ADVANCED /UREOTHELIAL CARCINOMA
USO 07-134: Phase II Study of Perifosine for Patients with Metastatic Carcinoma of the Kidney who have Progressed on a VEGF Receptor Inhibitor
USO 08-036 (Coming Soon): Axitinib (AG-013736) as Second Line Therapy for Metastatic Renal Cell Cancer: AXIS Trial
USO 09013:An open-label, phase Ib, dose-escalation study of the safety and pharmacology of the anti-cd40 monoclonal antibody SGN-40 administered in combination with bortezomib (Velcade, PS-341) in patients with relapsed or refractory multiple myeloma
USO 07-083: Phase I Study of Oral Darinaspirin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas
Vidaza Patient Registry (AVIDA): A Prospective, Multi-Center, Observational Study Compiling Data on the Natural History and Management of Patients Receiving Vidaza
USO 07-168: A Prospective, Non-Interventional Multicenter Registry in Iron Overloaded Lower-Risk Myelodysplastic Patients
USO 08-044: Randomized, Open-Label, Phase 3 Study of Pemetrexed plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
USO 06-135: Phase II Trial of Sunitinib Malate in Previously Untreated NSCLS Patients > 70
USO 07-190: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination with Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC)
VEEDA Oncology GEM017: A Phase I followed by a Randomized, Phase II Study of Carboplatin and Etoposide with or without Obatoclax Administered Every 3 Weeks to Patients with Extensive-State Small Cell Lung Cancer (ES-SCLC)
CALGB 79803: A phase III chemoprevention trial of Selenium
supplementation in persons with resected Stage I Non-Small
Cell Lung Cancer
USO 04-107: Randomized Phase III Study of Docetaxel
or Pemetrexed with or without Cetuximab in Patients
with Recurrent or Progressive Non-Small Cell Lung Cancer
after Platinum-Based Therapy
USO 07-031: A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given In Combination with Carboplatin and Paclitaxel In Patients with Advanced Non-Small Cell Lung Cancer
USO 06-206: A Multi-center Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva (erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-Positive Tumors
USO 04-107: Randomized Phase III Study of Docetaxel or Pemetrexed with or without Cetuximab in Patients with Recurrent or Progressive Non-Small Cell Lung Cancer after Platinum-Based Therapy (IMCL CP02-0452)
USO 07-027: Open-label phase 1b study of erlotinib plus bevacizumab and IMO-2055 in patients with non-small cell lung cancer who have progressed following initial chmotherapy for advanced or metastatic disease
USO 07-050: A Randomized, Open-label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemptherapy
USO 06-071: A Randomized, Placebo-controlled, Double-Blind, Multicenter Phase 2 Study with a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients with Non-small Cell Lung carcinoma After Failure In Up to Two Chemotherapeutic Regimens for Advanced Disease (SNDX-275-0401)
USO 06-108: A Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE and Dexamethasone (VD) versus VELCADE, Melphalan, and Prednisone (VMP) (UPFRONT)
USO 06-168: A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma
Please Refer To The Phase I List
No Active Studies
CALGB 90201: A Randomized Double Blind, Placebo-Controlled Phase III
Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related
Events in Men with Prostate Cancer Metastatic to Bone
No Active Studies
SYNTA PROTOCOL 4783-08: A Randomized, Double-Blind, Phase 3 Trial of STA-4783 in Combination with Paclitaxel versus Paclitaxel Alone for Treatment of Chemotherapy Naive Subjects with Stage IV Metastatic Melanoma (SYMMETRY)
| 
l